Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Graft Versus Host Disease (GvHD) Market & Epidemiology Forecast 2026-2036 - Set to Reach New Growth Milestones Through 2036 as Targeted, Cell-Based, and Microbiome Therapies Advance

globenewswire.com
ABBV AbbVie is listed as an active company in the Graft Versus Host Disease (GvHD) market, indicating their involvement in the development or commercialization of GvHD therapies. JNJ Johnson & Johnson is identified as a key company active in the Graft Versus Host Disease (GvHD) market, suggesting their participation in related therapeutic areas. SNY Sanofi is mentioned as a key company active in the Graft Versus Host Disease (GvHD) market, indicating their involvement in the development or commercialization of GvHD therapies. INCY Incyte is listed as a key company active in the Graft Versus Host Disease (GvHD) market, suggesting their involvement in related therapeutic areas and potential for growth in this segment. SNDX Syndax Pharmaceuticals is named as a key company active in the Graft Versus Host Disease (GvHD) market, indicating their engagement in developing therapies for this condition. NVS Novartis is identified as a key company active in the Graft Versus Host Disease (GvHD) market, suggesting their involvement in the development or commercialization of GvHD therapies. BMY Bristol Myers Squibb is listed as a key company active in the Graft Versus Host Disease (GvHD) market, indicating their participation in the development of GvHD treatments. MRK Merck & Co. is mentioned as a key company active in the Graft Versus Host Disease (GvHD) market, suggesting their involvement in the development or commercialization of GvHD therapies. REGN Regeneron Pharmaceuticals is mentioned as a key company active in the Graft Versus Host Disease (GvHD) market, indicating their involvement in the development or commercialization of GvHD therapies. GILD Gilead Sciences is mentioned as a key company active in the Graft Versus Host Disease (GvHD) market, indicating their involvement in the development or commercialization of GvHD therapies. AMGN Amgen is mentioned as a key company active in the Graft Versus Host Disease (GvHD) market, indicating their involvement in the development or commercialization of GvHD therapies. BIIB Biogen is mentioned as a key company active in the Graft Versus Host Disease (GvHD) market, indicating their involvement in the development or commercialization of GvHD therapies. AZN AstraZeneca is mentioned as a key company active in the Graft Versus Host Disease (GvHD) market, indicating their involvement in the development or commercialization of GvHD therapies.

Graft Versus Host Disease (GvHD) Market & Epidemiology Forecast 2026-2036 - Set to Reach New Growth Milestones Through 2036 as Targeted, Cell-Based, and Microbiome Therapies Advance Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Graft Versus Host Disease - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

The report provides a comprehensive assessment of the Graft Versus Host Disease market, epidemiology, treatment landscape, emerging therapies, and commercial opportunities across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

The Graft Versus Host Disease market across the 7MM was valued at approximately USD 2.1 billion in 2025 and is projected to expand at a compound annual growth rate of 6.4% from 2026 to 2036. Growth is expected to be supported by an increasing number of allogeneic hematopoietic stem cell transplant procedures, improved post-transplant survival, greater diagnosis rates, and wider adoption of targeted and advanced therapeutic approaches.

The United States represented the largest regional market in 2025, generating approximately USD 1.6 billion and accounting for about 77% of the total 7MM GvHD market. Its leadership is expected to continue through 2036, supported by established transplant infrastructure, favorable adoption of novel therapies, strong clinical development activity, and broad access to specialty care.

Graft Versus Host Disease Epidemiology Highlights

Approximately 52,000 GvHD cases were reported across the 7MM in 2025. The patient population is forecast to increase through 2036 as transplant volumes and survival rates rise. In the United States, approximately 4,300 acute GvHD cases and 18,500 five-year prevalent chronic GvHD cases were estimated in 2025.

Current Graft Versus Host Disease Treatment Landscape

The GvHD treatment landscape is transitioning from broadly layered immunosuppression toward mechanism-specific therapies designed to regulate immune signaling, control inflammation, reduce fibrosis, and support immune tolerance. Ruxolitinib (JAKAFI/JAKAVI), ibrutinib (IMBRUVICA), belumosudil (REZUROCK), axatilimab-csfr (NIKTIMVO), and remestemcel-L (RYONCIL/TEMCELL HS) are among the therapies influencing current market dynamics.

Ruxolitinib remains a leading revenue-generating GvHD therapy, supported by approvals for steroid-refractory acute and chronic GvHD in major markets. Ibrutinib is established in chronic GvHD after prior systemic treatment, while belumosudil provides selective ROCK2 inhibition for previously treated chronic GvHD. Axatilimab-csfr expands the treatment landscape through CSF-1R inhibition, targeting monocyte- and macrophage-associated inflammation and fibrosis.

Despite recent progress, significant unmet needs remain. Existing prophylactic approaches may provide suboptimal protection in high-risk transplant settings and can be associated with cumulative toxicity. Priorities include earlier diagnosis, improved risk stratification, optimized combination regimens, durable immune tolerance, enhanced understanding of chronic GvHD pathophysiology, and safer treatments for refractory disease.

Graft Versus Host Disease Pipeline and Competitive Landscape

The GvHD pipeline includes microbiome-based therapies, cellular products, monoclonal antibodies, and small molecules targeting acute GvHD, chronic GvHD, and prophylaxis. Prominent investigational candidates include MaaT013 (XERVYTEG), RGI-2001, CYP-001, ivarmacitinib, siplizumab, and itolizumab.

MaaT013 is being evaluated as a pooled-donor microbiome therapy for gastrointestinal-predominant, steroid-refractory acute GvHD. A pivotal Phase III program is ongoing, and a European marketing authorization application was submitted in June 2025. The candidate has also received orphan drug designation from the US FDA and European Medicines Agency.

RGI-2001 is in development for acute GvHD prophylaxis and has generated positive Phase IIb findings, supporting plans for further late-stage evaluation. CYP-001 has been studied in combination with corticosteroids for high-risk acute GvHD under a cleared US FDA investigational new drug application. Selected pipeline therapies are anticipated to reach the US market before 2028, subject to successful clinical and regulatory outcomes.

Key companies active in the Graft Versus Host Disease market include AbbVie, Johnson & Johnson, Sanofi, Incyte, Syndax Pharmaceuticals, Novartis, Neovii, Mundipharma, Shionogi, JCR Pharmaceuticals, Bristol Myers Squibb, MaaT Pharma, REGiMMUNE, and other biotechnology and pharmaceutical developers.

Report Coverage and Strategic Insights

The report evaluates historical and forecast GvHD market size, therapy-level market share, drug uptake, peak patient share, pricing trends, reimbursement, treatment practices, clinical development, and country-specific epidemiology. It also assesses approved and emerging therapies by efficacy, safety, administration route, dosing frequency, market-entry timing, probability of success, and addressable patient population.

The Graft Versus Host Disease market is entering a period of substantial clinical and commercial change. Continued innovation in targeted biologics, small molecules, cell-based immunomodulators, and microbiome-restorative therapies is expected to shift treatment toward more precise disease control, prevention, immune tolerance, and tissue repair. These developments are likely to create meaningful opportunities for established market leaders and emerging GvHD companies through 2036.

Graft versus Host Disease (GvHD) Market Report: Epidemiology, Treatment Landscape and Forecast Through 2027

The Graft versus Host Disease (GvHD) market report delivers a comprehensive assessment of disease classification, symptoms, etiology, pathophysiology and diagnostic trends. It also reviews GvHD treatment algorithms and clinical guidelines across the seven major markets (7MM), comprising the United States, Germany, France, Italy, Spain, the United Kingdom and Japan.

Graft versus Host Disease Epidemiology Analysis

The epidemiology section examines historical data, the reported patient population and forecast trends across the 7MM during the 2016-2027 study period. The analysis incorporates published research, market assumptions and insights from key opinion leaders to evaluate diagnosed, incident, prevalent and treatable patient populations.

Epidemiological segmentation includes acute Graft versus Host Disease (aGvHD) and chronic Graft versus Host Disease (cGvHD), with acute cases further categorized by Grades I, II, III and IV. The report also assesses diagnosed incident cases of hematopoietic stem cell transplantation (HSCT), including first allogeneic HSCT procedures, diagnosed incident cases of aGvHD and cGvHD, four-year diagnosed prevalent cases of aGvHD and five-year diagnosed prevalent cases of cGvHD.

In 2016, the seven major GvHD markets recorded 53,601 diagnosed incident HSCT cases, including 21,408 incident cases involving first allogeneic HSCT. The total was forecast to increase through 2027. Among the 7MM, the United States accounted for the highest number of diagnosed incident aGvHD and cGvHD cases associated with first allogeneic HSCT, followed by Germany.

GvHD Drugs and Clinical Pipeline

The report provides detailed profiles of marketed GvHD therapies and late-stage pipeline candidates in Phase II and Phase III development. Coverage includes clinical trial activity, pharmacological action, regulatory approvals, patents, licensing agreements, strategic collaborations, treatment advantages and limitations, and relevant industry developments.

During the report's study period, the GvHD treatment landscape relied substantially on off-label therapies. Assessed treatment classes include corticosteroids such as methylprednisolone and prednisolone; calcineurin inhibitors such as cyclosporine; IL-2 receptor alpha inhibitors; TNF-alpha inhibitors; co-stimulatory blockers; mTOR inhibitors; solid-organ transplant therapies; antineoplastic agents; and additional biologic therapies.

The report identifies three approved products within the analyzed market and timeframe: Imbruvica for chronic GvHD in the United States, remestemcel-L for acute GvHD in Japan and Grafalon for GvHD prophylaxis in Germany. Individual drug chapters evaluate these products alongside promising emerging therapies expected to influence future GvHD treatment strategies.

Graft versus Host Disease Market Outlook

The GvHD market outlook analyzes historical performance, the competitive environment and forecast market trends. It evaluates the influence of available therapies, unmet medical needs, market drivers, access barriers, technological developments and demand for improved treatment options.

Market assessments consider annual therapy costs, patient eligibility criteria, mechanisms of action, treatment adherence, addressable patient segments, anticipated launch timing, competitive positioning, brand value and key opinion leader perspectives. Supporting tables and graphs present market data for efficient comparison and strategic analysis.

The Graft versus Host Disease market is segmented into prophylaxis and therapeutics, with the therapeutics category divided into acute and chronic GvHD. The combined 7MM market was valued at USD 353.5 million in 2016 and was projected to expand at a compound annual growth rate through 2027.

GvHD Drug Uptake and Commercial Opportunity

The drug uptake analysis evaluates therapies launched or expected to launch during the 2016-2027 forecast period. It reviews market uptake by product, patient adoption by therapy and projected drug sales. The analysis also compares market share, commercial potential and the factors supporting rapid adoption, helping stakeholders assess competitive opportunities and inform financial, regulatory and portfolio-planning decisions.

Individual therapy forecasts are segmented across GvHD prophylaxis and treatment, providing a structured view of expected product performance within acute and chronic Graft versus Host Disease markets.

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this report visit https://www.researchandmarkets.com/r/clr5dd

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.